Bimzelx, bimekizumab
Named-patient access overview. Bimzelx is coordinated by Reserve Meds for international patients through cross-border sourcing coordinated with your treating doctor.
Ask about Bimzelx
Tell us the medicine and your country. We reply within one business day. On WhatsApp we usually reply the same day.
About Bimzelx
Bimzelx (bimekizumab) is manufactured by UCB Pharma and indicated for moderate-to-severe plaque psoriasis, active psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe hidradenitis suppurativa in adults. It is a subcutaneous IL-17A / IL-17F dual inhibitor (pre-filled pen or syringe) approved by the US FDA in 2023 and may be accessible to international patients through Named Patient Program or personal-import pathways.
Case active and ready to skip the regulatory walkthrough? Ask about a medicine or WhatsApp us.
How Reserve Meds coordinates Bimzelx
- Patient or treating physician submits a named-patient request.
- Clinical team verifies appropriateness of Bimzelx for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific NPP / personal-import documentation is prepared.
- Bimzelx is sourced from a US-licensed pharmaceutical wholesale partner with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy (cold-chain where required).
Access by country
Reserve Meds publishes a detailed country deep-dive for Bimzelx in every market we coordinate. Each page below covers the destination-country regulatory pathway (named-patient framework), how quotes work, indicative timelines, physician-credential requirements, and cold-chain handling for the route into that country. Tap any country to read the full deep-dive.
Start a request for Bimzelx
Send us the medicine and your country. We reply within one business day with case-specific feasibility, timeline, and a formal quote.